subcutaneous injection of denosumab every 6 months
Sponsors
Department of Endocrine and breast cancer, Kyoto Prefectural University of medicine, Kyoto Prefectural Universuty of Medicine, Kyoto Prefectural University of medicine
Conditions
Breast Cancerbreast cancer
Phase 2
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant setting
Active, not recruitingJPRN-UMIN000013863
Start: 2013-08-21Target: 100Updated: 2026-06-29
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant setting
Active, not recruitingJPRN-UMIN000027425
Start: 2016-01-08Target: 100Updated: 2026-06-29